Amber Meshell Yates MD (She/Her)
Pediatric Anemia and Red Blood Cell Hematology
Medical Director, Medical Affairs, Agios Pharmaceuticals
Join to View Full Profile
88 Sidney StCambridge, MA 02139
Dr. Yates is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Amber Yates is a Pediatric Hematologist/Oncologist based in Houston, TX, specializing in pediatric hemoglobinopathy. She completed her medical degree at LSU School of Medicine and further training in pediatrics (UT-Memphis) and pediatric hematology/oncology (St. Jude Children's Research Hospital). She practiced at Texas Children's Hospital for nearly a decade as a pediatric hematologist with an appointment in the Department of Pediatrics at Baylor of College. Currently she is Senior Medical Director of Global Medical Affairs at Agios Pharmaceuticals. Her expertise encompasses thalassemia, sickle-cell anemia, and other red blood cell disorders. Dr. Yates has published several noted articles and participated in multiple clinical trials related to pediatric hematology-oncology.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2006 - 2010- University of TennesseeResidency, Pediatrics, 2003 - 2006
LSU School of Medicine in ShreveportClass of 2003
Northeast Louisiana UniversityBS, Biology, Magna cum Laude, 1995 - 1999
Certifications & Licensure
TX State Medical License 2011 - 2027
TN State Medical License 2006 - 2013
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Medical Educators Institute American Society of Hematology, 2017
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload Start of enrollment: 2015 Oct 21
- Shared-Decision Making for Hydroxyurea Start of enrollment: 2018 Jul 12
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein
The Lancet. Haematology. 2025-01-01 - 9 citationsHealth Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report.Amber M Yates, Banu Aygun, Rachelle Nuss, Zora R Rogers,
Pediatrics. 2024-08-01 - 5 citationsA phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay.John D Odom, Hitha Amin, Charul Gijavanekar, Sarah H. Elsea, Stephen F. Kralik
American Journal of Medical Genetics. Part A. 2021-09-12
Books/Book Chapters
Abstracts/Posters
- Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle...Amber M Yates, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell DiseaseAmber M Yates, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Treatment Advances in Sickle Cell DiseaseOctober 2019
- Sickle Cell DiseaseMay 2019
- ASH 2018: How Social Media Has Helped My Career/Practice as a HematologistDecember 2018
Press Mentions
Social Media Can Help Doctors Stay up to DateDecember 11th, 2018
Committees
- Executive Committee Member, American Academy of Pediatrics Section of Hematology-Oncology 2018 - 2025
Professional Memberships
- Fellow
- Member
- American Society of Pediatric Hematology-OncologyMember
Industry Relationships
- Medical Director, Agios PharmaceuticalsMedical Director (SCD), Global Medical AffairsDisclosure: Employment, Stockholder2021 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
